Related Experiment Video
Updated: Aug 7, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
New trends in development of antimycobacterial compounds
M Biava1, G C Porretta, D Deidda
1Dipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente Attive, Università "La Sapienza", P.le A Moro 5, 00185 Rome, Italy. Mariangela.Biava@uniroma1.it
Abstract:
The resurgence of tuberculosis and the surge of multidrug-resistant clinical isolates of Mycobacterium tuberculosis have reaffirmed tuberculosis as a primary public health concern. In this review we describe some new findings on the pharmacological status of fluoroquinolones derivatives (Gatifloxacin, Moxifloxacin and Sitafloxacin), new macrolides (Clarithromycin, Azithromycin and Roxithromycin), new rifamycin derivatives (Rifapentin, Rifabutin and Rifalazil) and new oxazolidinones (Linezolid and PNU 100480). We describe also other type of agents that are being developed as antimycobacterial drugs. Some of these are under clinical investigation, while others are considered to be promising candidates for future development. Among them, nitroimidazopyrans, new ketolides, Isoxyl (ISO), pyrroles derived from BM 212, Mefloquine and Diarylquinoline R207910 are discussed. We also describe the mechanism of drug resistance in mycobacteria, as well as new potential targets.
More Related Videos
10:24Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
Published on: May 22, 2026
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Related Concept Videos
Development of Antibiotic Resistance
Antimicrobial Effectiveness
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antifungal Agents